Overview

Topical Tranexamic Acid for Bilateral Breast Reduction Surgery

Status:
Not yet recruiting

Trial end date:
2023-10-01

Target enrollment:
0

Participant gender:
Female

Summary

Hematoma is a common complication of bilateral breast reduction (BBR) surgery. This can lead to pain and discomfort experienced by the patient, in addition to greater use of valuable healthcare resources. Previous studies have shown correlation between the use of tranexamic acid (TXA), an anti-fibrinolytic, and reduced post-surgical bleeding complication events. In this randomized control trial (RCT) evaluation TXA use in BBR, for which one breast will be randomized to have TXA applied topically, while the other will have normal saline (NS) placebo applied. The primary objective of this prospective blinded randomized control trial study is to determine if the administration of topical TXA in BBR reduces the incidence of surgical site hematoma compared to placebo within 2 weeks following surgery. The results of this study will be used to inform the design of a larger multicentered RCT on TXA in breast surgery.

Phase:

Phase 3

Accepts Healthy Volunteers?

Details

Lead Sponsor:

McMaster University

Treatments:

Tranexamic Acid

Criteria

Inclusion Criteria:

- Are 18 years or older;

- Are undergoing bilateral breast reduction at either Hamilton Health Sciences or St.
Joseph's Hospital Hamilton.

Exclusion Criteria:

- Taking therapeutic anticoagulation;

- Taking antiplatelet drugs;

- Pregnant or breast feeding;

- Allergic to TXA;

- Cannot provide informed consent;

- Have a documented coagulopathy or bleeding disorder, acquired disturbances of colour
vision, subarachnoid hemorrhage, hematuria, irregular menstrual bleeding, or seizure
disorder.